Reduced risk of lung cancer with metformin therapy in diabetic patients: A systematic review and meta-analysis

American Journal of Epidemiology

Volumn 180, Issue 1, 2014, Pages 11-14

  Zhang, Zhi Jiang ^a   Bi, Yongyi ^a   Li, Shiyue ^a   Zhang, Qingjun ^b   Zhao, Genming ^c   Guo, Yi ^a   Song, Qibin ^d  

^a WUHAN UNIVERSITY   (China)

^b Hubei Center for Disease Control and Prevention   (China)

^c FUDAN UNIVERSITY   (China)

^d RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

chemoprevention; diabetes; lung cancer; metformin; smoking

Indexed keywords

METFORMIN;

CANCER; DIABETES; DRUG; EPIDEMIOLOGY; HEALTH RISK; HETEROGENEITY; META-ANALYSIS; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTOR; SMOKING;

CANCER LOCALIZATION; CANCER RISK; DIABETES MELLITUS; DIABETIC PATIENT; HUMAN; LUNG CANCER; META ANALYSIS; OBESITY; RESPIRATORY SYSTEM; REVIEW; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW;

CHEMOPREVENTION; DIABETES; LUNG CANCER; METFORMIN; SMOKING;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; METFORMIN; RISK; RISK FACTORS; SMOKING;

EID: 84903990488     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu124     Document Type: Review

References (29)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Chen Y, Ebenstein A, Greenstone M, et al. Evidence on the impact of sustained exposure to air pollution on life expectancy from China's Huai River policy. Proc Natl Acad Sci U S A. 2013;110(32):12936-12941.
3. Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol. 2013;14(9): 813-822.
4. Kamangar F, Qiao YL, Yu B, et al. Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1562-1564.
5. Goodman GE, Thornquist MD, Balmes J, et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst. 2004;96(23):1743-1750.
6. Kelly K, Kittelson J, Franklin WA, et al. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev Res (Phila). 2009;2(5):440-449.
7. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294(1):56-65.
8. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3(11):1451-1461.
9. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34(10): 2323-2328.
10. Zhang ZJ, Zheng ZJ, Shi R, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(7): 2347-2353.
11. Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis [published online ahead of print January 27, 2014]. Diabetes Obes Metab. (doi:10.1111/dom.12267).
12. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012;35(1):119-124.
13. Mazzone PJ, Rai H, Beukemann M, et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012;12:410.
14. Hsieh MC, Lee TC, Cheng SM, et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782.
15. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9): 1620-1625.
16. Storozhuk Y, Hopmans SN, Sanli T, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATMand AMPK. Br J Cancer. 2013; 108(10):2021-2032.
17. Wu N, Gu C, Gu H, et al. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma. 2011;58(6):482-490.
18. Algire C, Zakikhani M, Blouin MJ, et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008;15(3): 833-839.
19. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila). 2010;3(9):1066-1076.
20. Smiechowski BB, Azoulay L, Yin H, et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care. 2013;36(1):124-129.
21. Ferrara A, Lewis JD, Quesenberry CP Jr, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34(4):923-929.
22. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
24. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9): 820-826.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
26. Xu X, Su S, Barnes VA, et al. A genome-wide methylation study on obesity: differential variability and differential methylation. Epigenetics. 2013;8(5):522-533.
27. Chang CH, Lin JW, Wu LC, et al. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(7):E1170-E1175.
28. Li C, Zhao G, Okoro CA, et al. Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes: findings from the 2009 Behavioral Risk Factor Surveillance System. Diabetes Care. 2013;36(6):1569-1576.
29. Currie CJ, Poole CD, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):668-677.